SYNACT PHARMA AB |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6.84 SEK | -0.94% |
|
-8.68% | -22.54% |
| Mar. 20 | Sweden's SynAct Pharma Names New CEO | MT |
| Mar. 20 | SynAct Pharma AB Elects New Board Members and Chairman at Extraordinary General Meeting | CI |
Valuation
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 97.44 | 118.9 | 1,081 | 3,703 | 2,416 | 314.1 |
| Enterprise Value (EV) 1 | 90.33 | 115.3 | 1,067 | 3,682 | 2,310 | 252.3 |
| P/E ratio | -3.89 x | -4.99 x | -36 x | -53.1 x | -22.7 x | -1.33 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | - | - | - | - | - | - |
| EV / Revenue | - | - | - | - | - | - |
| EV / EBITDA | -3.21 x | -4.71 x | -34.5 x | - | - | -3.92 x |
| EV / FCF | -4.96 x | -12.2 x | -87.9 x | -84.9 x | -27.5 x | 9.88 x |
| FCF Yield | -20.2% | -8.2% | -1.14% | -1.18% | -3.64% | 10.1% |
| Price to Book | 9.45 x | 11.7 x | 68.1 x | 177 x | 19.1 x | 1.78 x |
| Nbr of stocks (in thousands) | 14,675 | 14,675 | 24,406 | 26,006 | 29,648 | 35,571 |
| Reference price 2 | 6.640 | 8.100 | 44.30 | 142.4 | 81.50 | 8.830 |
| Announcement Date | 4/17/19 | 4/9/20 | 4/19/21 | 4/29/22 | 4/13/23 | 3/26/24 |
1SEK in Million2SEK
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales | - | - | - | - | - | - |
| EBITDA 1 | -28.13 | -24.48 | -30.9 | - | - | -64.36 |
| EBIT 1 | -28.39 | -24.8 | -31.28 | -76.7 | -101.6 | -138.9 |
| Operating Margin | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | -28.24 | -27.1 | -31.3 | -76.81 | -107.1 | -224.3 |
| Net income 1 | -23.45 | -23.96 | -26.55 | -69.3 | -99.2 | -215.8 |
| Net margin | - | - | - | - | - | - |
| EPS 2 | -1.705 | -1.624 | -1.232 | -2.681 | -3.596 | -6.635 |
| Free Cash Flow 1 | -18.23 | -9.453 | -12.13 | -43.37 | -84.11 | 25.55 |
| FCF margin | - | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 4/17/19 | 4/9/20 | 4/19/21 | 4/29/22 | 4/13/23 | 3/26/24 |
1SEK in Million2SEK
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q4 | 2023 Q2 | 2023 Q3 | 2023 Q4 |
|---|---|---|---|---|
| Net sales | - | - | - | - |
| EBITDA 1 | - | - | - | -91.06 |
| EBIT 1 | - | - | -31.69 | -91.06 |
| Operating Margin | - | - | - | - |
| Earnings before Tax (EBT) 1 | - | - | -31.99 | -90.54 |
| Net income 1 | -26.21 | -43.51 | -31.88 | -90.54 |
| Net margin | - | - | - | - |
| EPS 2 | -1.010 | -1.370 | -1.000 | -2.580 |
| Dividend per Share | - | - | - | - |
| Announcement Date | 2/11/22 | 8/4/23 | 10/24/23 | 2/23/24 |
1SEK in Million2SEK
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - |
| Net Cash position 1 | 7.12 | 3.56 | 14.5 | 20.9 | 106 | 61.8 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow 1 | -18.2 | -9.45 | -12.1 | -43.4 | -84.1 | 25.6 |
| ROE (net income / shareholders' equity) | -202% | -201% | -189% | -377% | -135% | -143% |
| ROA (Net income/ Total Assets) | -121% | -81.9% | -82.3% | -160% | -70.2% | -46.9% |
| Assets 1 | 19.33 | 29.24 | 32.25 | 43.34 | 141.4 | 460.5 |
| Book Value Per Share 2 | 0.7000 | 0.6900 | 0.6500 | 0.8000 | 4.270 | 4.950 |
| Cash Flow per Share 2 | 0.4800 | 0.1800 | 0.6000 | 0.9200 | 3.650 | 1.750 |
| Capex | - | - | - | - | - | - |
| Capex / Sales | - | - | - | - | - | - |
| Announcement Date | 4/17/19 | 4/9/20 | 4/19/21 | 4/29/22 | 4/13/23 | 3/26/24 |
1SEK in Million2SEK
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -22.54% | 22.15M | |
| +0.67% | 42.19B | |
| +44.30% | 40.15B | |
| -6.20% | 28.31B | |
| +6.55% | 24.63B | |
| -21.66% | 18.2B | |
| +29.96% | 12.01B | |
| -1.57% | 11.76B | |
| +16.03% | 10.4B | |
| -4.80% | 9.94B |
- Stock Market
- Equities
- SYNACT Stock
- Financials SynAct Pharma AB
